Latest Headlines
-
BD Launches Combination Test For COVID-19, Influenza A/B And Respiratory Syncytial Virus
6/30/2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that the BD MAX™ Respiratory Viral Panel (RVP), a new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV), has been CE marked to the IVD directive 98/79/EC.
-
Elevation Diagnostics Moves To Fitzsimons Innovation Community Campus In Aurora, Colorado
6/29/2022
Elevation Diagnostics LLC announced that they have relocated and expanded their operations to a new, state-of-the-art facility located on the Fitzsimons Innovation Community Campus.
-
Anitoa Launches Molecular Test (PCR) For Monkeypox
6/29/2022
Anitoa Systems, market leader in fast, portable molecular testing, today announced the availability of a CE-marked turn-key PCR solution for testing Monkeypox.
-
Labcorp Plans Laboratory Expansion In Japan Through BML Collaboration
6/28/2022
Labcorp a leading global life sciences company, today announced that it is enhancing its central laboratory presence and drug development capabilities in Japan through an expansion of CB Trial Laboratory, the central laboratory co-managed by Labcorp Drug Development and BML, a leading Japanese provider of clinical laboratory testing services.
-
Community Health Network And Grail Partner To Offer Galleri Multi-Cancer Early Detection Test In Central Indiana
6/28/2022
Indianapolis-based Community Health Network and GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced a partnership to offer Galleri, GRAIL’s multi-cancer early detection (MCED) blood test, to individuals at Community Health Network’s sites of care.
-
Roche Launches The VENTANA DP 600 Slide Scanner For Digital Pathology, Enhancing Patient Care With Precision Diagnostics
6/28/2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE launch of the next-generation VENTANA DP 600 slide scanner (CE-IVD marked).
-
Seegene Develops PCR Test To Detect Monkeypox Virus
6/28/2022
Seegene Inc. (KQ965390), South Korea's leading molecular diagnostics (MDx) company has developed a PCR test to detect the monkeypox virus.
-
Akoya Biosciences To Partner With Acrivon Therapeutics For The Clinical Development Of Acrivon’s Proprietary OncoSignature® Test Into A Companion Diagnostic
6/28/2022
Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, and Acrivon Therapeutics, Inc., a clinical-stage oncology therapeutics company with proprietary technologies driving a new era of precision-based medicine, today announced an agreement to co-develop, validate, and commercialize Acrivon’s OncoSignature® test, a first-of-its-kind companion diagnostic.
-
Cepheid And BioGX Announce Collaboration To Develop Monkeypox PCR Test For The GeneXpert® System
6/27/2022
Cepheid and BioGX today announced a collaboration between the two companies to deliver a PCR test for Monkeypox that will run on the GeneXpert system. With a global installed base of over 40,000 GeneXpert systems in 180 countries, this test could be deployed quickly in multiple settings where actionable information is needed.
-
Berry Oncology Launches HIFI Pan-Cancer Screening, A Multi-Cancer Early Screening Product For Detecting Six High-Risk Cancers At One Time
6/23/2022
On June 23, Berry Oncology, a global leading company specialized in genomic testing and early cancer screening, announced the launch of its innovative one-time precision product HIFI Pan-Cancer Screening, which is an early multi-cancer screening product developed based on the company's proprietary HIFI technology platform.